Francis Collins
Showing 16–22 of 22 transcripts.
- Milken Institute1h 3m
Chasing Cures: Reinventing the Business of Medicine
Melissa Stevens, John Noseworthy, Francis Collins, Mark Rothera, Melinda Richter, Monsef Slaoui
A panel of industry leaders and NIH officials advocates transforming biomedical research through open innovation models like the Accelerating Medicines Partnership, which pools $30 billion in funding to address major diseases by sharing data across pre-competitive collaborations. The discussion highlights a strategic shift toward patient-centric trials using real-world evidence and wearable technology to accelerate discovery while redefining value to include safety and patient-defined outcomes over mere cost containment. Looking ahead, experts anticipate breakthroughs in bio-electronic medicine and precision therapies, driven by regulatory reforms for orphan drugs and non-traditional partnerships that prioritize patient access over traditional discovery-to-commercialization silos.
- Milken Institute1h 11m
Lunch Panel: A Cure for What Ails Us: Celebrating the Impact of Science (updated II)
Nancy Brown, Francis Collins, Thomas Frieden, Andrew von Eschenbach, Michael Milken, Mike Milken, Tom Frieden, Andy Van Eschenbach, Jack Andreyka
A comprehensive analysis of global bioscience reveals a dramatic increase in life expectancy and major breakthroughs in disease eradication, such as the near-elimination of polio and HIV management through programs like PEPFAR. Despite these successes, the sector faces a critical funding crisis where declining NIH grant success rates and inflation-adjusted budget cuts threaten the pipeline of young researchers and the translation of genetic discoveries into new treatments. Strategic initiatives like the Brain Initiative, precision medicine efforts, and the shift toward prevention are now essential to address rising chronic disease burdens and sustain the bioscience industry as a primary driver of US economic growth.
- Milken Institute1h 0m
Bioscience Discoveries That Will Blow Your Mind (updated)
Jack Andraka, David Baltimore, Francis Collins, Tejal Desai, Aydogan Ozcan, Margaret Anderson
Prominent figures including Jack Andraka, Tejal Desai, and NIH Director Francis Collins present breakthroughs in nanotechnology, genomics, and cellular engineering that promise to revolutionize early cancer detection, drug delivery, and precision medicine. While these innovations leverage falling sequencing costs, portable diagnostic devices, and adaptive sensor platforms to bridge the gap between molecular discovery and clinical treatment, panelists express deep concern over a 20% decline in real research funding. The collective discourse underscores an urgent need to redirect resources toward young innovators and high-risk projects to sustain the momentum of this biological renaissance.
- Milken Institute58 min
The Role of Universities in Accelerating Bioscience Research
David Baltimore, Joel Burdick, James Economou, Michael Quick, Owen Witte, Stephen Mayo, Steve Mayo, Nick, Francis Collins, Remy, Joe Boistak, Charles, Eric Green, Ray Deshaies
A consortium of leading academic figures, including Nobel Laureate David Baltimore and experts from Caltech, UCLA, and USC, convened to evaluate the intersection of biological engineering and clinical translation in the face of funding constraints. The panel detailed successful strategies for "engineered immunity" projects, such as converting muscle cells into antibody producers and conducting early-stage human trials within university settings, while highlighting the critical need for interdisciplinary programs that bridge the gap between engineering PhDs and MDs. Despite progress, participants identified a persistent "valley of death" in early-stage financing and urged a cultural shift toward professional management and team-based funding mechanisms to sustain innovation.
- Milken Institute1h 12m
Lunch Panel: A Cure for What Ails Us: Celebrating the Impact of Science
Nancy Brown, Francis Collins, Thomas Frieden, Andrew von Eschenbach, Michael Milken
The bioscience forum highlighted the sector's massive contribution to increased global life expectancy and economic growth while emphasizing that flat budgets and inflation have critically reduced NIH grant success rates to below 20%. Distinguished leaders such as Francis Collins and Tom Frieden warned that sustained funding cuts and a 90% treatment-versus-prevention spending imbalance threaten American innovation and the careers of young researchers. Despite these financial constraints, the event underscored significant breakthroughs in areas like genomic medicine and disease eradication, with panelists urging renewed investment to maintain global health leadership and drive future discoveries.
- Milken Institute1h 0m
Bioscience Discoveries That Will Blow Your Mind
Jack Andraka, David Baltimore, Francis Collins, Tejal Desai, Aydogan Ozcan, Margaret Anderson
A panel of leading scientists including Jack Andraka, Tejal Desai, David Baltimore, and Francis Collins outlined breakthrough innovations in cancer detection, gene therapy, and nanotechnology while highlighting the transformative potential of open-access data. Despite rapid advancements in genomic sequencing and portable diagnostics, experts warned of a critical decline in U.S. biomedical funding that is discouraging young researchers from pursuing high-risk scientific careers. The discussion concluded with calls to establish special grant programs for early-career innovators and to restore emphasis on curiosity-driven education to sustain future scientific progress.
- Milken Institute1h 15m
The Promise of the Bioscience Century
Paul Irving, Mike Milken, Eric Cantor, Paul Chu, Jeff, Bernardo Zavala, Jr., Bernard Harris, Andy von Eschenbach, Peggy, Francis Collins, Chris Austin
This event analyzes the critical role of bioscience in driving global economic growth and societal well-being while highlighting China's aggressive $308 billion investment program that threatens to surpass U.S. leadership. Panelists discuss strategic institutional responses, such as DARPA's high-risk research model and the FDA's regulatory innovations, which have accelerated breakthroughs in prosthetics, personalized medicine, and disease prevention. However, fiscal constraints and shifting global demographics necessitate sustained bipartisan funding to preserve the United States' status as a central hub for scientific innovation and global health security.